20/2/2024, 12:33:03 pm

What’s after Revlimid for Dr Reddy’s, Cipla, and Sun Pharma?

Frontline pharma majors - Cipla, Sun Pharma, and Dr Reddy’s - have seen a surge in earnings due to the high-margin blockbuster cancer drug Revlimid. However, as the patent for Revlimid is set to expire in 2026, these companies will need to find other sources of revenue to maintain growth. Dr Reddy's focuses on acquisitions and faster product filings.